TY - JOUR
T1 - Engineering a self-navigated MnARK nanovaccine for inducing potent protective immunity against novel coronavirus
AU - Wang, Yaling
AU - Xie, Yuping
AU - Luo, Jia
AU - Guo, Mengyu
AU - Hu, Xuhao
AU - Chen, Xi
AU - Chen, Ziwei
AU - Lu, Xinyi
AU - Mao, Lichun
AU - Zhang, Kai
AU - Wei, Liangnian
AU - Ma, Yunfei
AU - Wang, Ruixin
AU - Zhou, Jia
AU - He, Chunyan
AU - Zhang, Yufang
AU - Zhang, Ye
AU - Chen, Sisi
AU - Shen, Lijuan
AU - Chen, Yun
AU - Qiu, Nasha
AU - Liu, Ying
AU - Cui, Yanyan
AU - Liao, Guoyang
AU - Liu, Ye
AU - Chen, Chunying
N1 - Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/6
Y1 - 2021/6
N2 - Effective vaccines are vital to fight against the COVID-19 global pandemic. As a critical component of a subunit vaccine, the adjuvant is responsible for strengthening the antigen-induced immune responses. Here, we present a new nanovaccine that comprising the Receptor-Binding Domain (RBD) of spike protein and the manganese nanoadjuvant (MnARK), which induces humoral and cellular responses. Notably, even at a 5-fold lower antigen dose and with fewer injections, the MnARK vaccine immunized mice showed stronger neutralizing abilities against the infection of the pseudovirus (~270-fold) and live coronavirus (>8-fold) in vitro than that of Alum-adsorbed RBD vaccine (Alu-RBD). Furthermore, we found that the effective co-delivery of RBD antigen and MnARK to lymph nodes (LNs) elicited an increased cellular internalization and the activation of immune cells, including DCs, CD4+ and CD8+ T lymphocytes. Our findings highlight the importance of MnARK adjuvant in the design of novel coronavirus vaccines and provide a rationale strategy to design protective vaccines through promoting cellular internalization and the activation of immune-related pathways.
AB - Effective vaccines are vital to fight against the COVID-19 global pandemic. As a critical component of a subunit vaccine, the adjuvant is responsible for strengthening the antigen-induced immune responses. Here, we present a new nanovaccine that comprising the Receptor-Binding Domain (RBD) of spike protein and the manganese nanoadjuvant (MnARK), which induces humoral and cellular responses. Notably, even at a 5-fold lower antigen dose and with fewer injections, the MnARK vaccine immunized mice showed stronger neutralizing abilities against the infection of the pseudovirus (~270-fold) and live coronavirus (>8-fold) in vitro than that of Alum-adsorbed RBD vaccine (Alu-RBD). Furthermore, we found that the effective co-delivery of RBD antigen and MnARK to lymph nodes (LNs) elicited an increased cellular internalization and the activation of immune cells, including DCs, CD4+ and CD8+ T lymphocytes. Our findings highlight the importance of MnARK adjuvant in the design of novel coronavirus vaccines and provide a rationale strategy to design protective vaccines through promoting cellular internalization and the activation of immune-related pathways.
UR - http://www.scopus.com/inward/record.url?scp=85103091495&partnerID=8YFLogxK
U2 - 10.1016/j.nantod.2021.101139
DO - 10.1016/j.nantod.2021.101139
M3 - Article
AN - SCOPUS:85103091495
SN - 1748-0132
VL - 38
JO - Nano Today
JF - Nano Today
M1 - 101139
ER -
